Anthera Announces That Data From the Phase 2 BRIGHT-SC Study Has Been Accepted as a Late Breaking Abstract at the ASN Kidney ...
November 02 2016 - 12:59PM
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that an
abstract of the interim data from the Phase 2 BRIGHT-SC clinical
study evaluating the treatment effect of blisibimod in patients
with biopsy-proven IgA Nephropathy (IgAN) has been accepted as a
late-breaking poster presentation at the 2016 American Society of
Nephrology’s Kidney Week Annual Meeting.
“These data provide hope to patients with IgAN, for whom no
approved therapy exists, that a targeted therapy may slow disease
progression,” said Jonathan Barratt, MD, Reader in the Department
of Infection, Immunity & Inflammation, University of Leicester,
Honorary Consultant Nephrologist at Leicester General Hospital, and
Head of the Postgraduate Specialty School of Clinical Academic
Training at Health Education East Midlands.
“The observations from the BRIGHT-SC study provide clear
evidence of blisibimod’s effects on proteinuria, B cells and
immunoglobulins which are central to disease pathology, and support
the hypothesis that B-cell activation underlies kidney damage. We
are pleased to have this opportunity to share these data with the
nephrology community,” said Renee Martin, Anthera’s Senior Vice
President of Medical Sciences.
The poster entitled, “Effects of Blisibimod, a Selective
Inhibitor of B-Cell Activating Factor, in Patients with IgA
Nephropathy” is scheduled to be presented by Dr. Barratt on Friday,
November 18, from 10 AM to 12 PM (Central Time).
The abstract will be available online at www.asn-online.org and
the poster will be available on the Anthera website after
completion of the session.
About Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing products to treat serious and
life-threatening diseases, including lupus, lupus with
glomerulonephritis, IgA nephropathy, and exocrine pancreatic
insufficiency due to cystic fibrosis. Additional information on the
Company can be found at www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on Anthera's expectations as
of the date of this press release and are subject to certain risks
and uncertainties that could cause actual results to differ
materially as set forth in Anthera's public filings with the SEC,
including Anthera's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2016. Anthera disclaims any intent or obligation to
update any forward-looking statements, whether because of new
information, future events or otherwise, except as required by
applicable law.
Contact Information:
Nikhil Agarwal of Anthera Pharmaceuticals, Inc.,
nagarwal@anthera.com or 510.856.5600 x5621
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Apr 2023 to Apr 2024